Compare USPH & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USPH | RAPP |
|---|---|---|
| Founded | 1990 | 2022 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1996 | 2024 |
| Metric | USPH | RAPP |
|---|---|---|
| Price | $77.62 | $28.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $105.60 | $48.50 |
| AVG Volume (30 Days) | 185.8K | ★ 313.3K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $780,990,000.00 | N/A |
| Revenue This Year | $9.44 | N/A |
| Revenue Next Year | $6.43 | N/A |
| P/E Ratio | $56.23 | ★ N/A |
| Revenue Growth | ★ 16.33 | N/A |
| 52 Week Low | $62.77 | $7.73 |
| 52 Week High | $93.50 | $42.27 |
| Indicator | USPH | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 33.74 | 49.34 |
| Support Level | $77.28 | $25.40 |
| Resistance Level | $83.08 | $29.84 |
| Average True Range (ATR) | 3.20 | 2.01 |
| MACD | -0.58 | -0.01 |
| Stochastic Oscillator | 34.40 | 46.56 |
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.